高效管理患者
功能希望继续完善
App is temporarily unavailable
Description
易陪伴——更高效的临床试验
面向医生、CRC的患者和受试者管理工具
===主要功能===
【患者管理】
【访视管理】
【数据统计】
【事件记录】
【项目管理】
【智能匹配】
面向医生、CRC的患者和受试者管理工具
===主要功能===
【患者管理】
【访视管理】
【数据统计】
【事件记录】
【项目管理】
【智能匹配】
Screenshots
易陪伴 FAQ
-
Is 易陪伴 free?
Yes, 易陪伴 is completely free and it doesn't have any in-app purchases or subscriptions.
-
Is 易陪伴 legit?
Not enough reviews to make a reliable assessment. The app needs more user feedback.
Thanks for the vote -
How much does 易陪伴 cost?
易陪伴 is free.
-
What is 易陪伴 revenue?
To get estimated revenue of 易陪伴 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.
User Rating
App is not rated in Kazakhstan yet.
Ratings History
易陪伴 Reviews
易陪伴 Installs
Last 30 days
易陪伴 Revenue
Last 30 days易陪伴 Revenue and Downloads
Gain valuable insights into 易陪伴 performance with our analytics.
Sign up now to access downloads, revenue, and more.
Sign up now to access downloads, revenue, and more.
App Info
- Category
- Medical
- Publisher
-
Susu Technology (Tianjin) Co
- Languages
- Chinese
- Recent release
- 2.4.2 (4 weeks ago )
- Released on
- Dec 13, 2020 (4 years ago )
- Also available in
- China , Portugal , South Korea , Kuwait , Kazakhstan , Lebanon , Mexico , Malaysia , Nigeria , Netherlands , Norway , New Zealand , Peru , Philippines , Pakistan , Poland , Japan , Romania , Russia , Saudi Arabia , Sweden , Singapore , Thailand , Türkiye , Taiwan , Ukraine , United States , Vietnam , South Africa , Egypt , Austria , Australia , Azerbaijan , Belgium , Belarus , Switzerland , Chile , Colombia , Czechia , Germany , Denmark , Algeria , United Arab Emirates , Spain , Finland , France , United Kingdom , Greece , Hong Kong SAR China , Hungary , Indonesia , Ireland , Israel , India , Italy , Brazil
- Last Updated
- 3 months ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.